Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

Alcobra Ltd. (Nasdaq: ADHD)

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. *


Please contact us with your proposals. Thank you!
Period Start 2014-10-10 existent
Period End 2017-09-27 merger announced
  Group Arcturus Therapeutics (Group)
  Today Arcturus Therapeutics Ltd. (Nasdaq: ARCT)
  Successor Arcturus Therapeutics Ltd. (Nasdaq: ARCT)
Products Industry MDX (Alcobra Ltd)
  Industry 2 drug development
Region Region Tel Aviv
  Country Israel
  Street 132 Derech Menachem Begin
  City 6701101 Tel Aviv
    Address record changed: 2017-06-26
Basic data Employees n. a.
  Currency USD
  Profit -24,609,000 (2016-12-31)
  Cash 2,304,000 (2016-12-31)
    * Document for �About Section�: Alcobra Ltd.. (1/9/15). "Press Release: Alcobra Ltd. Prices Public Offering of Ordinary Shares". Tel Aviv.
Record changed: 2018-10-31


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Arcturus Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top